REG - Genflow Biosciences - Total Voting Rights

Genflow BiosciencesAnnouncement

31/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260331:nRSe3521Ya&default-theme=true

RNS Number : 3521Y  Genflow Biosciences PLC  31 March 2026

31 March 2026

 

Genflow Biosciences plc

("Genflow" or the "Company")

 

Total Voting Rights

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company")
announces that the total issued share capital of the Company as at 31 March
2026 consists of 535,653,205 ordinary shares of £0.0003 each, none of which
are held in treasury. Therefore, the total number of voting rights in the
Company is 535,653,205.

The figure of 535,653,205 ordinary shares may be used by shareholders of the
Company as the denominator for the calculations by which they will determine
if they are required to notify their investment in, or a change in their
interest in, the share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

About Genflow Biosciences

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies for age-related diseases, with the goal
of promoting longer and healthier lives while mitigating the financial,
emotional, and social impacts of a fast-growing aging global population.
Genflow's lead compound, GF-1002, works through the delivery of a centenarian
variant of the SIRT6 gene which has yielded promising preclinical results.
Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs, include a clinical trial that will explore the potential benefits of
GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis),
the most prevalent chronic liver disease for which there is no effective
treatments. Please visit www.genflowbio.com (http://www.genflowbio.com)   and
follow the Company on LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true) and
X (https://x.com/genflowbio) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRPPUUAWUPQPUQ



            Copyright 2019 Regulatory News Service, all rights reserved